X

Sign up for Equitymaster's free daily newsletter, The 5 Minute WrapUp and get access to our latest Multibagger guide (2018 Edition) on picking money-making stocks.

This is an entirely free service. No payments are to be made.


Download Now Subscribe to our free daily e-letter, The 5 Minute WrapUp and get this complimentary report.
We hate spam as much as you do. Check out our Privacy Policy and Terms Of Use.
Compare ALEMBIC PHARMA with STRIDES PHARMA SCIENCE - Equitymaster

Helping You Build Wealth With Honest Research
Since 1996. Try Now

  • MyStocks

MEMBER'S LOGINX

     
Login Failure
   
     
   
     
 
 
 
(Please do not use this option on a public machine)
 
     
 
 
 
  Sign Up | Forgot Password?  

ALEMBIC PHARMA vs STRIDES PHARMA SCIENCE - Comparison Results

STRIDES PHARMA SCIENCE 
   Change

Strides Arcolab is an Indian pharmaceutical company headquartered at Bangalore. The company is primarily involved in two businesses notably the pharma business and the specialized sterile products business branded as Agila. This segment focuses large... More

DO YOU LIKE THESE REPORTS? TELL US!

Current Valuations

    ALEMBIC PHARMA STRIDES PHARMA SCIENCE ALEMBIC PHARMA/
STRIDES PHARMA SCIENCE
 
P/E (TTM) x 20.3 51.8 39.3% View Chart
P/BV x 4.8 1.1 424.9% View Chart
Dividend Yield % 0.7 0.4 164.5%  

Financials

 ALEMBIC PHARMA   STRIDES PHARMA SCIENCE
EQUITY SHARE DATA
    ALEMBIC PHARMA
Mar-18
STRIDES PHARMA SCIENCE
Mar-18
ALEMBIC PHARMA/
STRIDES PHARMA SCIENCE
5-Yr Chart
Click to enlarge
High Rs6451,147 56.2%   
Low Rs470642 73.2%   
Sales per share (Unadj.) Rs166.1317.2 52.3%  
Earnings per share (Unadj.) Rs21.97.8 279.1%  
Cash flow per share (Unadj.) Rs27.525.1 109.7%  
Dividends per share (Unadj.) Rs4.002.00 200.0%  
Dividend yield (eoy) %0.70.2 320.9%  
Book value per share (Unadj.) Rs117.8274.3 42.9%  
Shares outstanding (eoy) m188.5289.50 210.6%   
Bonus/Rights/Conversions -ESOP-  
Price / Sales ratio x3.42.8 119.0%   
Avg P/E ratio x25.5114.0 22.3%  
P/CF ratio (eoy) x20.335.7 56.8%  
Price / Book Value ratio x4.73.3 145.1%  
Dividend payout %18.325.5 71.6%   
Avg Mkt Cap Rs m105,09080,058 131.3%   
No. of employees `000NA2.5 0.0%   
Total wages/salary Rs m6,2284,341 143.5%   
Avg. sales/employee Rs ThNM11,325.8-  
Avg. wages/employee Rs ThNM1,731.4-  
Avg. net profit/employee Rs ThNM280.1-  
INCOME DATA
Net Sales Rs m31,30828,394 110.3%  
Other income Rs m70941 7.5%   
Total revenues Rs m31,37829,334 107.0%   
Gross profit Rs m6,4313,965 162.2%  
Depreciation Rs m1,0551,540 68.5%   
Interest Rs m341,962 1.7%   
Profit before tax Rs m5,4131,403 385.7%   
Minority Interest Rs m00-   
Prior Period Items Rs m-81-168 48.2%   
Extraordinary Inc (Exp) Rs m0-436 0.0%   
Tax Rs m1,20497 1,236.9%   
Profit after tax Rs m4,128702 588.0%  
Gross profit margin %20.514.0 147.1%  
Effective tax rate %22.26.9 320.7%   
Net profit margin %13.22.5 533.2%  
BALANCE SHEET DATA
Current assets Rs m18,24724,836 73.5%   
Current liabilities Rs m11,23518,993 59.2%   
Net working cap to sales %22.420.6 108.8%  
Current ratio x1.61.3 124.2%  
Inventory Days Days8671 120.6%  
Debtors Days Days61113 54.1%  
Net fixed assets Rs m20,03534,289 58.4%   
Share capital Rs m377895 42.1%   
"Free" reserves Rs m21,82423,651 92.3%   
Net worth Rs m22,20124,546 90.4%   
Long term debt Rs m5,00015,513 32.2%   
Total assets Rs m39,41165,437 60.2%  
Interest coverage x160.21.7 9,340.5%   
Debt to equity ratio x0.20.6 35.6%  
Sales to assets ratio x0.80.4 183.1%   
Return on assets %10.64.1 259.4%  
Return on equity %18.62.9 650.1%  
Return on capital %19.76.9 286.1%  
Exports to sales %46.40-   
Imports to sales %10.50-   
Exports (fob) Rs m14,535NA-   
Imports (cif) Rs m3,288NA-   
Fx inflow Rs m14,72215,697 93.8%   
Fx outflow Rs m7,026735 955.4%   
Net fx Rs m7,69614,962 51.4%   
CASH FLOW
From Operations Rs m3,1241,871 167.0%  
From Investments Rs m-8,8445,826 -151.8%  
From Financial Activity Rs m5,026-10,157 -49.5%  
Net Cashflow Rs m-693-2,615 26.5%  

Share Holding

Indian Promoters % 74.1 27.7 267.5%  
Foreign collaborators % 0.0 0.0 -  
Indian inst/Mut Fund % 2.9 37.8 7.7%  
FIIs % 9.1 8.6 105.8%  
ADR/GDR % 0.0 0.0 -  
Free float % 13.9 25.9 53.7%  
Shareholders   49,328 56,241 87.7%  
Pledged promoter(s) holding % 0.0 0.0 -  
NM: Not Meaningful
Source: Company Annual Reports, Regulatory Filings, Equitymaster

Compare ALEMBIC PHARMA With:   ABBOTT INDIA  NATCO PHARMA  AJANTA PHARMA  PFIZER  ALKEM LABORATORIES  

Compare ALEMBIC PHARMA With:   MYLAN (US)  ACTAVIS (US)  ADCOCK INGRAM (S. Africa)  TEVA PHARMA (Israel)  



Today's Market

Macroeconomic Cues Guide the Markets This Week(Podcast)

Global markets remained in pressure this week. Pound fell sharply as risk of chaotic Brexit rose.

Related Views on News

STRIDES PHARMA SCIENCE Announces Quarterly Results (2QFY19); Net Profit Down 72.2% (Quarterly Result Update)

Nov 6, 2018 | Updated on Nov 6, 2018

For the quarter ended September 2018, STRIDES PHARMA SCIENCE has posted a net profit of Rs 54 m (down 72.2% YoY). Sales on the other hand came in at Rs 7 bn (down 26.4% YoY). Read on for a complete analysis of STRIDES PHARMA SCIENCE's quarterly results.

ALEMBIC PHARMA Announces Quarterly Results (2QFY19); Net Profit Up 61.0% (Quarterly Result Update)

Oct 23, 2018 | Updated on Oct 23, 2018

For the quarter ended September 2018, ALEMBIC PHARMA has posted a net profit of Rs 2 bn (up 61.0% YoY). Sales on the other hand came in at Rs 11 bn (up 42.8% YoY). Read on for a complete analysis of ALEMBIC PHARMA's quarterly results.

Aster DM Healthcare (IPO)

Feb 10, 2018

Should you subscribe to the IPO of Aster DM Healthcare Ltd?

Dr Reddy's: Milestone Payment Drives Sales (Quarterly Results Update - Detailed)

Feb 9, 2018

US business was hit by pricing pressure although there was growth sequentially led by new product launches.

Lupin: US market Declines Due to Higher Base Effect of FY17 (Quarterly Results Update - Detailed)

Feb 9, 2018

Price erosion in generic US drugs continues but seems to be bottoming out.

More Views on News

Most Popular

These Are the Kind of Blue Chips You Should Invest In(The 5 Minute Wrapup)

Nov 9, 2018

All blue chip companies are large caps but all large caps are not blue chips.

Get this Small Cap Logistics Company at a 16% Discount Right Now...(Profit Hunter)

Nov 6, 2018

If you turn the clock back, the current macroeconomic climate is nothing new. The markets have seen them all, and every downcycle has been succeeded by gravity defying gains...more so in the small cap space. This time will be no different.

This Was a Large Cap. But Was It Safe?(Chart Of The Day)

Nov 9, 2018

Investing in large caps is not always safe. Consider the right metrics to judge the safety and quality of large caps.

Why the Realty Sector's Recovery Has Been Delayed(Sector Info)

Nov 15, 2018

NBFC and IL&FS crisis have worsened the realty sector woes. Is there a light at the end of the tunnel for real estate sector?

Does it Make Sense to Invest in Offshore Funds?(Outside View)

Nov 6, 2018

Many investors prefer to invest in offshore funds because of the rupee depreciation and on-going downtrend in the markets, but it is to be invested only when there is no option available to invest in India.

More

Small Investments
BIG Returns

Zero To Millions Guide 2019
Get our special report, Zero To Millions
(2019 Edition) Now!
We will never sell or rent your email id.
Please read our Terms

ALEMBIC PHARMA SHARE PRICE


Nov 16, 2018 (Close)

TRACK ALEMBIC PHARMA

  • Track your investment in ALEMBIC PHARMA with Equitymaster's Portfolio Tracker. Set live price alerts, get research alerts and more. Get access now...
  • Add To MyStocks

MORE ON ALEMBIC PHARMA

ALEMBIC PHARMA 5-YR ANALYSIS

COMPARE ALEMBIC PHARMA WITH

MARKET STATS